Enveric Biosciences (NASDAQ:ENVB) Releases Earnings Results

Enveric Biosciences (NASDAQ:ENVBGet Free Report) issued its earnings results on Monday. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.30, Yahoo Finance reports.

Enveric Biosciences Trading Down 0.8 %

NASDAQ:ENVB traded down $0.00 during trading hours on Tuesday, hitting $0.52. The stock had a trading volume of 59,666 shares, compared to its average volume of 2,395,429. The company has a market cap of $4.14 million, a PE ratio of -0.08 and a beta of 0.74. The business has a 50 day simple moving average of $0.59 and a two-hundred day simple moving average of $0.83. Enveric Biosciences has a 1-year low of $0.41 and a 1-year high of $2.92.

About Enveric Biosciences

(Get Free Report)

Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.

Further Reading

Earnings History for Enveric Biosciences (NASDAQ:ENVB)

Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.